What is the main purpose of the approved Employee Stock Purchase Plans (ESPPs)?

The amended and restated ESPPs are designed to allow eligible employees to purchase Gilead common stock at a discount, fostering employee ownership and aligning their interests with those of the company's shareholders.

What was the outcome of the advisory vote on executive compensation?

Gilead's stockholders approved, on an advisory basis, the compensation paid to the company's Named Executive Officers. They also supported conducting these advisory votes on an annual basis going forward.

Were there any significant stockholder proposals that were approved?

No, all stockholder proposals presented at the meeting did not receive majority approval. These proposals covered topics such as director nominations, shareholder rights for special meetings, and reporting on patent exclusivity impacts.

Who will serve as Gilead's independent auditor for the upcoming fiscal year?

Ernst & Young LLP has been ratified by Gilead's stockholders to serve as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

GILD 8-K: Leadership Changes & Shareholder Matters

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on May 4, 2023, reporting on the outcomes of its Annual Meeting of Stockholders held on May 3, 2023. The primary focus for investors is the overwhelming approval of amendments to the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. This indicates strong stockholder support for employee equity participation and potentially the company's strategy to retain and incentivize its workforce through stock ownership. Additionally, the filing confirms the election of nine directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2023. The meeting also included advisory votes on executive compensation, with stockholders approving the compensation of Named Executive Officers and supporting annual advisory votes on executive compensation going forward. Notably, several stockholder proposals, including those related to director nominations, special meeting rights for different share classes, and the impact of patent exclusivities on product access, did not receive majority support from stockholders. This suggests that management's recommendations on these matters were largely followed.

Key Highlights

1Stockholders overwhelmingly approved amended and restated Employee Stock Purchase Plans (ESPPs) for both U.S. and International employees.
2All nine incumbent directors were elected to serve for the upcoming year.
3Ernst & Young LLP was ratified as Gilead's independent registered public accounting firm for fiscal year 2023.
4Stockholders approved, on an advisory basis, the compensation of Gilead's Named Executive Officers.
5Gilead will conduct future advisory votes on executive compensation on an annual basis, as per stockholder preference.
6Several stockholder proposals, including those concerning director nomination processes, equal voting rights for different share classes, and patent exclusivity reporting, failed to gain majority approval.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (May 5, 2023)

Summary

Key Highlights

Frequently Asked Questions